Skip to Main Content
Welcome to theĀ Scientist.comĀ Marketplace

Go to Main Navigation

BP7069b

Ketohexokinase (KHK) Antibody (C-term) Blocking peptide

Abcepta

DETAILS

  • Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
  • Gene Id: 3795
  • Category: Peptides; Blocking Peptides
  • Subtitle: Synthetic peptide
  • Gene Name: KHK
  • Other Names: Ketohexokinase, Hepatic fructokinase, KHK
  • Availability: 2 weeks
  • Bio Background: Ketohexokinase (KHK), or fructokinase, catalyzes conversion of fructose to fructose-1-phosphate. Splice variant 1 is the highly active form found in liver, renal cortex, and small intestine, while splice variant 2 is the lower activity form found in most other tissues. KHK, like glucokinase (GCK) and glucokinase regulator (GCKR), is present in both liver and pancreatic islets. The inhibition of GCK by GCKR is blocked by binding of fructose-1-phosphate to GCKR. The chromosomal proximity of the metabolically connected GCKR and KHK genes has a genetic linkage in type 2 diabetes. Fructosuria, or hepatic fructokinase deficiency, is a benign, asymptomatic defect of intermediary metabolism associated with heterozygosity for G50R and A43T mutations in KHK.
  • Primary Accession: P50053
  • Targetspecificity: The synthetic peptide sequence used to generate the antibody AP7069b was selected from the C-term region of human KHK. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.